GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » EPS without NRI

Annovis Bio (Annovis Bio) EPS without NRI : $-6.22 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio EPS without NRI?

Annovis Bio's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-2.33. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.22.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -78.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -115.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Annovis Bio's EPS without NRI or its related term are showing as below:

ANVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -172   Med: -102.8   Max: -77.4
Current: -78.4

During the past 7 years, Annovis Bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -77.40% per year. The lowest was -172.00% per year. And the median was -102.80% per year.

ANVS's 3-Year EPS without NRI Growth Rate is ranked worse than
95.62% of 1301 companies
in the Biotechnology industry
Industry Median: 5.1 vs ANVS: -78.40

Annovis Bio's EPS (Diluted) for the three months ended in Dec. 2023 was $-2.33. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.22.

Annovis Bio's EPS (Basic) for the three months ended in Dec. 2023 was $-2.33. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.22.


Annovis Bio EPS without NRI Historical Data

The historical data trend for Annovis Bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio EPS without NRI Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -0.15 -0.87 -1.90 -3.10 -4.92

Annovis Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -1.19 -1.07 -1.63 -2.33

Competitive Comparison of Annovis Bio's EPS without NRI

For the Biotechnology subindustry, Annovis Bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annovis Bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Annovis Bio's PE Ratio without NRI falls into.



Annovis Bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Annovis Bio  (NYSE:ANVS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Annovis Bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of Annovis Bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Annovis Bio (Annovis Bio) Business Description

Traded in Other Exchanges
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company include ANVS-401, ANVS-405 and ANVS-301.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831

Annovis Bio (Annovis Bio) Headlines